Through combining anti-EGFR antibody (Cetuximab), as a molecular therapeutic, with hybrid plasmonic magnetic NPs, Yokoyama et al. [138] observed that EGFR-targeted C225-NPs are selectively taken up by EGFR-expressing NSCLC cells and had synergistic antitumor properties, also inducing apoptosis and autophagy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.